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Parkinson’s disease is characterized by the 
degeneration of dopaminergic neurons in the 
substantia nigra in the brain.1 The resulting lack 
of dopamine in the brain causes disruption of 
brain circuits, thereby provoking the core motor 
features of bradykinesia plus rest tremor or rigid-
ity.2 Levodopa, nonergot dopamine agonists and 
monoamine oxidase (MAO) inhibitors are effec-
tive in relieving the motor symptoms and signs 
of the disease.3 Levodopa is administered via the 
oral or duodenal route, and dopamine agonists 
are administered via the oral, transdermal or 
subcutaneous route. Several years after being 
diagnosed with Parkinson’s disease, many 
patients develop motor fluctuations as a result of 
a narrowing therapeutic window of levodopa4 in 
combination with a delayed onset of effect after 
orally administered levodopa due to irregular 
gastrointestinal absorption.5 This may lead to 
‘off periods’, in which Parkinson’s symptoms are 
poorly controlled6 and patients suffer from a 
variety of complaints such as bradykinesia, 
decreased mobility, tremor and autonomic or 
sensory symptoms.7 For patients with severe 
motor fluctuations on oral levodopa therapy, the 
only registered drug for termination of the off 
periods is subcutaneous apomorphine. After 
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Abstract
Background: Inhaled levodopa may quickly resolve off periods in Parkinson’s disease. Our aim 
was to determine the pharmacokinetics and tolerability of a new levodopa dry-powder inhaler.
Methods: A single-centre, single-ascending, single-dose–response study was performed. 
Over three visits, eight Parkinson’s disease patients (not in the ‘off state’) received by 
inhalation 30 mg or 60 mg levodopa, or their regular oral levodopa. Maximum levodopa 
plasma concentration (Cmax), time to maximum plasma concentration (Tmax) and area under the 
concentration time curve 0–180 min were determined. Spirometry was performed three times 
at each visit.
Results: After inhalation, levodopa Tmax occurred within 15 min in all participants, whereas 
after oral administration, Tmax ranged from 20 min to 90 min. The bioavailability of inhaled 
levodopa without carboxylase inhibitor was 53% relative to oral levodopa with carboxylase 
inhibitor. No change in lung-function parameters was observed and none of the patients 
experienced cough or dyspnoea. No correlation was observed between inhalation parameters 
and levodopa pharmacokinetic parameters.
Conclusion: Inhaled levodopa is well tolerated, absorbed faster than oral levodopa, and can be 
robustly administered over a range of inhalation flow profiles. It therefore appears suitable for 
the treatment of off periods in Parkinson’s disease.
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injection, an onset of effect of apomorphine is 
generally not seen within a 20-min lag time.8 
Since being in an off period causes a great bur-
den to the patient, a rapid onset of the effect is 
desired. Unfortunately, apomorphine is a strong 
emetic, causing nausea and vomiting on a regu-
lar basis. Patients using apomorphine therefore 
frequently require antiemetic drugs.9 Another 
disadvantage of apomorphine is its administra-
tion via (self) injection. In spite of improved 
needle technology, injection is considered bur-
densome by many patients.
An alternative strategy in daily practice for end-
ing an off episode is the oral administration of 
levodopa/benserazide dispersible tablets. Faster 
effect than standard levodopa formulations is 
expected. For dispersible levodopa to be effec-
tive, the levodopa needs to be absorbed via the 
small intestine. It is known that most off symp-
toms improve within about 30–60 min after 
administration of dispersible levodopa, but in 
some patients, improvement of symptoms is 
delayed or does not occur at all.10 After oral 
administration, the absolute bioavailability of 
immediate-release levodopa is 40–60%, com-
bined with a decarboxylase inhibitor, it raises to 
approximately 85%.11
The Cmax is reached after 1 h on average. 
However, it is known that food, especially pro-
teins, decreases the absorption rate of levodopa. 
Food also increases the time to the Cmax. 
Levodopa is metabolized mainly via decarboxy-
lation by the aromatic amino acid decarboxylase 
to dopamine, adrenaline, and noradrenaline and 
via O-methylation by catechol-O-methyltrans-
ferase (COMT) and MAO.12,13,14 Levodopa used 
in combination with a decarboxylase inhibitor 
has a relatively short plasma half-life time of 
approximately 90 min.15
Delivery of systemically acting drugs by inhala-
tion can offer various advantages compared with 
their oral administration.16,17 After correct pul-
monary administration, a major portion of the 
drug is immediately deposited on the absorbing 
membrane, which results in rapid absorption 
compared with oral administration. The drug is 
not subjected to the drug-metabolizing enzymes 
and efflux transporter activity of the gut and first-
pass metabolism of the liver that occurs after oral 
administration.16 Moreover, administration of 
levodopa by inhalation bypasses the irregular 
gastrointestinal absorption of levodopa in off 
periods, which is caused by irregular gastrointes-
tinal motility. In contrast, after inhalation, small 
molecules can be absorbed within seconds to 
minutes,16 which has been confirmed for levo-
dopa by Lipp et al.18 They showed that after inha-
lation of their levodopa formulation CVT301, the 
drug was rapidly absorbed into the bloodstream. 
Already 5 min after receiving 50 mg of CVT-301, 
67% of the participants showed a levodopa 
plasma concentration over 400 ng/ml. This rapid 
absorption clearly is an advantage when a quick 
response of a drug is desired, as in off periods in 
Parkinson’s disease. Pulmonary administration 
of levodopa is therefore considered a promising 
alternative to injected apomorphine or to dis-
persible levodopa tablets. This promise is further 
strengthened by the fact that Parkinson’s disease 
patients are generally capable to perform a cor-
rect inhalation manoeuvre during an off period.19
So far, the only described dry-powder inhalation 
system for levodopa is the CVT301.18 The 
CVT301 system is based on a spray-dried pow-
der containing only 50% levodopa, with 25% 
dipalmitoyl phosphatidylcholine, 15% sodium 
citrate, and 10% calcium chloride as excipients. 
The high load of excipients increases the amount 
of powder to be inhaled and may lead to side 
effects, such as cough. Motivated by the positive 
results from our study on inhalation manoeu-
vres, we developed a new dry-powder inhalation 
system for levodopa that contains 98% pure 
crystalline drug and only a minor amount (2%) 
of an endogenous excipient.20 Furthermore, the 
fact that this formulation contains only crystal-
line levodopa is expected to improve the stability 
of the final product. Being a preloaded, dispos-
able inhaler, the Cyclops® (PureIMS, Roden, 
the Netherlands) does not require the loading 
of capsules, contrary to CVT301, which makes 
it easier to use. Furthermore, the high resistance 
to airflow of the Cyclops may minimize the 
chance of cough reactions during inhalation.
In this article, we present the pharmacokinetic 
data of an unblinded single-centre, single-ascend-
ing, single-dose–response study of a pulmonary 
administered 30 mg and 60 mg levodopa with 2% 
L-leucine dry-powder dose in Parkinson’s disease 
patients. Besides the pharmacokinetic evaluation 
of inhaled levodopa, the tolerability of the airways 
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for inhaled dry-powder levodopa was assessed 
using spirometry data. Furthermore, by recording 
the inhalation flow profiles during dose adminis-
tration we examine the relationship between 
inhalation and pharmacokinetic parameters.
Materials and methods
Materials
Levodopa, European Pharmacopoeia quality, was 
supplied by Duchefa Farma (Haarlem, The 
Netherlands). L-leucine was purchased from 
Sigma-Aldrich (Zwijndrecht, The Netherlands). 
The levodopa was blended with 2% w/w L-leucine 
and micronized. Subsequently, the powder was 
weighed into blisters. Each blister contained 
30.3 mg powder, corresponding to 30 mg levo-
dopa. The inhaler used in this trial was the 
Cyclops® dry-powder inhaler (DPI).21
Informed consent and ethics
All procedures performed in this study were in 
accordance with the ethical standards of the 
institutional and national research committee 
and with the 1964 Helsinki declaration and its 
later amendments. The study protocol was 
approved by the official Dutch ethics committee 
‘Regionale toetsingscommissie patiëntgebonden 
onderzoek’ (RTPO) in Leeuwarden, The 
Netherlands (approval number RTPO949). All 
participants provided written informed consent 
for their participation in this study. The study 
was registered in the Dutch trial register www.
trialregister.nl (5435). The study was carried out 
in concordance with the International Council 
for Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human 
Use guidelines for Good Clinical Practice.
Study population
Eight participants with Parkinson’s disease were 
recruited from the outpatient clinic of the 
Department of Neurology and Clinical 
Neurophysiology of the Martini Hospital 
Groningen, the Netherlands. The study was per-
formed between October 2016 and March 2018.
The sample size calculation is based on the 
expected levodopa plasma concentration after 
10 min, since a rapid onset of effect is desired. 
Inhalation of 30 mg of CVT301 results in a plasma 
levodopa concentration of 425 ng/ml with a stand-
ard deviation of 95 ng/ml after 10 min. After 
administration of 100 mg of oral levodopa in the 
fasted state, this value is around 150 ng/ml. With a 
power of 0.8 and a type I error rate α of 0.05, the 
required sample size would be two study partici-
pants. Because of expected differences between 
CVT301 and the inhaler used in this study, a 
larger sample size of eight participants was 
assumed to be sufficient.
Patients were eligible if they were at least 18 years 
of age; diagnosed with Parkinson’s disease; cur-
rently on a stable levodopa regime with a maxi-
mum of four administrations per day and able to 
perform spirometry. Participants were excluded if 
they met one or more of the exclusion criteria. 
Exclusion criteria were: cognitive dysfunction that 
precludes good understanding of the instructions; 
being pregnant or breastfeeding; being known to 
suffer from active pulmonary disease; symptomatic 
orthostatic hypotension or using a COMT or 
MAO-B inhibitor.
Dosing
Over three visits, at least 7 days apart, the partici-
pants received a 30 mg inhalation powder levo-
dopa dose (visit one), a 60 mg (2 × 30 mg) 
inhalation powder levodopa dose (visit two) and 
their regular oral levodopa dose (visit three). The 
inhaled levodopa doses were chosen such that 
they would remain well below the acceptable sin-
gle oral dose of 250 mg, assuming a fourfold dose 
advantage by inhalation. The oral levodopa/
decarboxylase dose varied between 100/25 mg 
and 250/62.5 mg.
All visits and study-drug administration took 
place in the morning. All patients took their regu-
lar breakfast at home, of which the composition 
details were not collected. The participants were 
not allowed to take any food or drinks (except 
water) in the period 60 min before until 60 min 
after administration of the levodopa.
All levodopa doses administered in this study 
were at least 7.5 h after the last levodopa admin-
istration at home, which is five times the half-life 
time of levodopa plus decarboxylase inhibitor. 
The time of the last levodopa administration at 
home, the time of inhalation of the levodopa 
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powder and the time of oral administration of 
the levodopa in this study were recorded in case 
report forms.
Levodopa inhalation
The levodopa inhalation powder was adminis-
tered by inhalation through the mouth. Prior to 
levodopa inhalation, a lung technician trained 
participants in the correct handling of the inhaler 
device, including the different steps of a correct 
inhalation manoeuvre. For this training, an 
empty, instrumented inhaler was used. For 
measuring the flow curves through the inhaler, a 
differential pressure gauge (PD1 with MC2A 
measuring converter) was used (Hottinger, 
Baldwin Messtechnik, Darmstadt, Germany). 
The pressure drop across the inhaler was com-
puted into a flow rate, using a laptop loaded with 
LabViews software (National Instruments BV, 
The Netherlands).
The inhaler used for the levodopa administra-
tion was instrumented in the same manner. The 
generated flow curves were shown to the patient 
on the computer screen during training, as well 
as during inhalation of the levodopa, to enable 
the patient to adjust the desired inhalation 
effort. On the screen, the minimal required and 
maximal desired flow rate were indicated. The 
obtained flow curves during inhalation of the 
levodopa were also used to compute the inspira-
tory peak flow rates and inhaled volumes. For 
the 60 mg dose, the inhalation parameters of the 
first and second inhalation were averaged to 
enable further calculations. Because these 
parameters affect the dose emission from the 
inhaler, the aerosol generation process, as well 
as the lung deposition, they are a potential 
source of variation in the inhaled dose and its 
lung deposition. Hence, their evaluation poten-
tially allows for the explanation of unexpected 
pharmacokinetic results. After inhalation of the 
levodopa, the inhaler residue was determined by 
ultraviolet spectrophotometric analyses (UV-
1800 spectrophotometer Shimadzu Benelux, 
The Netherlands). The delivered dose was sub-
sequently calculated from blister dose minus 
inhaler residue. The fine particle dose (<5 µm), 
being 45% of the delivered dose at 4 kPa, was 
determined with a Sympatec HELOS BF laser 
diffractometer (Sympatec, GmbH, Clausthal-
Zellerfeld. Germany).
Blood sampling
Blood samples were collected before adminis-
tration of the levodopa (T = 0) and at T = 5, 
10, 15, 20, 30, 45, 60, 90 and 180 min after 
administration of the levodopa. The exact time 
of blood sampling was noted in the case report 
forms. Sampling was performed using an intra-
venous (IV) line filled with saline to avoid blood 
clotting of the system. To avoid dilution of the 
blood samples with saline, every first tube was 
rejected and every second tube was used for 
analysis. In case of problems with the IV line, a 
blood sample was drawn by venepuncture. The 
samples were collected in an ethylenediamine-
tetra-acetic acid tube. A research nurse took the 
blood samples.
Analytical methods
After collection, the samples were centrifuged for 
12 min at 2500 rpm. The plasma was then trans-
ferred to a Sarstedt cup with screw cap. For each 
ml of plasma, 10 mg reduced glutathione was 
added to prevent the degradation of levodopa. 
The samples were stored at −80°C until analysis. 
Levodopa concentrations were determined using 
liquid chromatography–tandem mass spectrome-
try (XLC-MS/MS). The limit of quantification 
was 1.0 nmol/l.
Spirometry
Spirometry was used to assess the tolerability of 
the airways for the inhaled dry-powder levodopa 
formulation. Spirometry was performed before 
administration of levodopa and ±35 and 
100 min after administration of levodopa, 
respectively. Forced expiratory volume in 1 s 
(FEV1), forced vital capacity (FVC) and maxi-
mum expiratory flow after 50% of the expired 
FVC (MEF50) were measured using a pneu- 
motachograph.
Spirometry was performed under the guidelines 
specified by the American Thoracic Society/
European Respiratory Society.22,23 An FEV1 
drop > 10% compared with baseline FEV1 was 
considered clinically relevant. Additionally, 
active questioning for cough and dyspnoea was 
performed during each spirometry session using 
the Borg Rating of Perceived Exertion.24 
Spirometry was performed by trained lung 
technicians.
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Pharmacokinetic evaluation
The linear trapezoidal method was used to calcu-
late the area under the concentration time curve 
(AUC) from T = 0 to T = 180 min (AUC 0–180). 
GraphPad Prism 7.0 (La Jolla, California USA) 
was used to calculate the AUCs. The maximum 
levodopa plasma concentration (Cmax) and the 
time to maximum plasma concentration (Tmax) 
were gathered from the obtained concentration 
time curves. The terminal elimination half-life 










= ∗  Equation 1
T is the Tmax minus the last timepoint of blood 
sampling; Ct is the last measured concentration in 
the concentration time curve and Cmax the maxi-
mum plasma concentration from the concentra-
tion time curve. The relative bioavailability from 
inhalation compared with that from oral adminis-








= =  Equation 2
where A refers to inhaled levodopa and B to oral 
levodopa, respectively.
Study objectives, design and study site
The primary objective of this study was the phar-
macokinetic evaluation of inhaled levodopa dry 
powder in comparison with oral levodopa.
The secondary objective was to assess the tolera-
bility of the airways for inhaled dry-powder levo-
dopa using spirometry data as a measure. The 




A total of eight patients were included in the 
study. Patient characteristics are presented in 
Table 1. From these patients, 232 blood samples 
were collected and analysed for levodopa plasma 
concentrations. Eight samples were missed due to 
issues with the IV line. The range of time spans 
between the moments of last levodopa adminis-
tration at home and administration of the study 
drug was 14–18 h (minimum/maximum). The 
delivered doses from the inhaler (all doses, all 
patients) were quite consistent and were on aver-
age 85.3% of the nominal dose (relative standard 
deviation = 5.6%; Table 2).
Levodopa pharmacokinetic data
The Figures 1(a) and 1(b) show the levodopa 
plasma concentrations after pulmonary adminis-
tration of 30 (a) and 60 mg (b) of levodopa, of 
which the Cmax values doubled approximately 
from 229.2 ± 62.1 ng/ml to 476.2 ± 132.7 ng/ml, 
respectively.
Plasma concentrations after oral administration 
of levodopa are shown in Figure 1(c). For easy 
comparison of the plasma levodopa concentra-
tions after oral administration, all administered 
oral doses (varying from 100 to 250 mg) were 
recalculated into plasma concentrations per 
100 mg oral levodopa.
Table 1. Patient characteristics.
Characteristics (n = 8)
Age (years) 50–59, n (%) 2 (25.0)
 60–69, n (%) 2 (25.0)
 70–79, n (%) 4 (50.0)
 Mean (SD) 67.9 (8.7)
Sex Male, n (%) 6 (75.0)
 Female, n (%) 2 (25.0)
BMI (kg/m2) Mean (SD) 27 (2.8)
Hoehn & Yahr score 1.5, n (%) 1 (12.5)
 2, n (%) 7 (87.5)
Oral levodopa dose 
(mg)
100, n (%) 4 (50.0)
 150, n (%) 3 (37.5)
 250, n (%) 1 (12.5)
BMI, body mass index; SD, standard deviation.
Therapeutic Advances in Chronic Disease 10
6 journals.sagepub.com/home/taj
After oral administration (100 mg levodopa) the 
mean Cmax was 1206.6 ± 448.7 ng/ml. The nor-
malized Cmax per milligram administered levo-
dopa (calculated from the delivered dose) was 
9.10 ng/ml after inhalation of 30 mg, 9.23 ng/ml 
after inhalation of 60 mg levodopa and 12.06 ng/
ml after oral administration.
The AUC per administered mg levodopa is 581.2 
± 127.6 min*ng/ml after inhalation of 30 mg lev-
odopa compared with 574.7 ± 139.9 min*ng/ml 
after inhalation of 60 mg levodopa. After oral 
administration, the AUC per mg is 1085.7 ± 
296.9 min*ng/ml. The relative bioavailability of 
inhaled levodopa in comparison with oral levo-
dopa is 53%.
Levodopa plasma concentrations varied strongly 
after oral administration of levodopa. This also 
results in large interindividual differences in the 
Tmax. The Tmax after oral administration was 
20 min for three participants, 45 min for one 
participant and 90 min for four participants 
[mean ± standard deviation (SD): 60 ± 35 min].
A summary of the plasma pharmacokinetic param-
eters of inhaled levodopa is shown in Table 2. 
After inhalation of levodopa, there was only a 
small interindividual variation in the Tmax for both 
dose levels, being 5 min for two participants, 
10 min for four participants and 15 min for two 
participants (mean ± SD: 10 ± 4 minutes).
The mean elimination half-life time in our study 
is 58.3 ± 12.8 min after inhalation of 30 mg, 57.8 
± 18.9 min after inhalation of 60 mg levodopa 
and 67.7 ± 20.6 min after oral administration of 
levodopa plus decarboxylase inhibitor.
Inhalation data
Table 3 shows the inhalation data obtained from 
flow volume curves that were recorded during 
inhalation of the levodopa by the study partici-
pants. The inhaled volumes varied from 1.1 l to 
4.2 l (mean ± SD: 2.6 ± 0.75). The maximum 
pressure drops across the inhaler varied between 
1.5 and 10.4 kPa (mean ± SD: 5.8 ± 2.4) with 
corresponding peak flow rates between 22.9 l/min 
and 59.9 l/min (mean ± SD: 43.4 ± 9.7). The 
variation of the inhalation characteristics is larger 
between the patients than within the patients and 
can at least partly be explained by differences in 
sex, age and size of the participants.
Table 2. Summary of plasma pharmacokinetic parameters of inhaled levodopa.
Participant Delivered 
dose (mg)
Cmax (ng/ml) Tmax (min) T ½ el (min) AUC 0–180 
(min*ng/ml)
V1 V2 V1 V2 V1 V2 V1 V2 V1 V2
1 23.6 54.2 159.5 567.2 5 10 65.5 48.9 11,712 32,755
2 26.4 52.4 337.0 584.7 10 10 49.2 42.7 15,825 28,953
3 25.3 52.6 228.6 628.2 10 15 58.8 55.2 13,676 38,130
4 26.0 52.2 307.8 446.5 15 15 34.0 76.9 21,541 41,475
5 22.5 47.2 211.0 574.6 15 10 68.1 36.6 15,214 26,340
6 25.8 54.1 188.1 418.9 10 10 57.5 46.4 12,219 24,365
7 25.8 47.8 182.4 308.2 10 5 57.2 62.4 11,904 21,125
8 26.1 52.6 218.8 281.3 5 5 76.3 92.9 15,085 24,072
Mean 25.2 51.6 229.2 476.2 10 10 58.3 57.8 14,647 29,652
SD 1.3 2.5 62.1 132.7 3.8 3.8 12.8 18.9 3216 7217
The delivered dose is the dose that has left the inhaler.
V1 = visit 1 (30 mg inhalation powder); V2 = visit 2 (60 mg inhalation powder).
AUC, area under the concentration time curve; Cmax, maximum levodopa plasma concentration; SD, standard deviation; T ½ 
el, elimination half-life time; Tmax, time to maximum plasma concentration.
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When relating the inhalation data from Table 3 to 
the plasma pharmacokinetics shown in Table 2, 
there is no clear relationship between inhaled vol-
umes, attained maximum pressure drops or maxi-
mum peak flows and the maximum plasma 
concentrations that were reached. R2 values from 
simple linear regression between these parameters 
do not exceed 0.022.
Spirometry
No significant change in lung-function parame-
ters (FEV1, FVC, MEF50) was observed after 
inhalation of either of the levodopa doses or after 
oral administration of levodopa. None of the 
patients experienced cough or dyspnoea during or 
after inhalation.
Discussion
In this study, we assessed the pharmacokinetics 
and tolerability in Parkinson’s disease patients of 
two doses of levodopa administered via a newly 
developed inhalation system, containing minimal 
amounts of excipient.
We demonstrated that a levodopa powder formu-
lation with 2% L-leucine administered via the 
Cyclops inhaler is rapidly absorbed into the sys-
temic circulation. In all patients, the Tmax with 
levodopa was reached faster after inhalation, that 
is, within 15 min, whereas after oral administra-
tion, Tmax with levodopa ranged from 20 min to 
90 min. The interindividual differences in both 
the Cmax and the time to Cmax were much larger 
for orally administered levodopa than for inhaled 
levodopa. In four out of eight patients, it took 
90 min to reach Cmax after oral administration. 
The slow rise of levodopa plasma concentrations 
in these patients may be the result of delayed gas-
tric emptying caused by not being in a true fasting 
state or by Parkinson’s disease. It is possible that 
such a slow rise of the levodopa plasma concen-
tration after oral administration makes oral levo-
dopa less effective for use in an acute setting such 
as the termination of off periods. In contrast, the 
results suggest that inhaled levodopa may be 
much more suitable to terminate an off period 
because of a consequential rapid rise in the plasma 
levodopa concentration.
There is no clear relationship between the 
inhaled volumes, maximal pressure drops, or 
peak flow rates and the maximal levodopa 
plasma concentrations that were achieved. This 
is mostly a consequence of the low variation in 
delivered dose between the study participants 
(Table 2). It implies that the combination of 
inhaler and levodopa formulation results in a 
robust pulmonary administration not sensitive 
to differences in inhalation technique or patient 
characteristics. One should bear in mind, how-
ever, that the differences in inhaler technique 
encountered in this study may not reflect the 
differences encountered in practice, because of 
the extensive inhalation instruction given to the 
study participants.
Figure 1. Plasma levodopa concentration (ng/ml) 
after inhaled or oral levodopa.
Plasma levodopa concentration (ng/ml) after (a) 30 mg 
inhaled levodopa, (b) 60 mg inhaled levodopa and (c) 100 mg 
oral levodopa. Individual plasma concentrations of eight 
patients are shown.
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The relative bioavailability of inhaled levodopa in 
comparison with oral levodopa is 53%, which is 
close to the fine particle fraction of the delivered 
dose of 45% and therefore appears to reflect the 
lung deposition fraction. After all, for effective 
deposition of inhalation powder in the airways, 
and thus absorption in the systemic circulation, a 
particle size between 1 and 5 µm is required.25 
However, the bioavailability of inhaled levodopa in 
this study is likely lowered by the absence of a 
decarboxylase inhibitor in the formulation. The 
levodopa inhalation powder does not contain a 
decarboxylase inhibitor, since its intended future 
use is on an ‘as needed’ basis as rescue medication 
on top of oral levodopa administered together with 
a decarboxylase inhibitor as maintenance therapy. 
Since the participants in this study had to postpone 
their own levodopa with decarboxylase inhibitor at 
least five half-life times before administration of 
the study levodopa, the pharmacokinetics of oral 
levodopa plus decarboxylase inhibitor is compared 
with that of inhaled levodopa without decarboxy-
lase inhibitor. Therefore, the AUC of inhaled levo-
dopa will be higher when used on an ‘as needed’ 
basis on top of maintenance therapy due to 
decreased peripheral conversion of levodopa to 
dopamine.14 Because the relative bioavailability is 
higher than the fine particle fraction (i.e. the frac-
tion suitable for deep lung deposition), our results 
imply that for effective absorption into the systemic 
circulation, deposition of levodopa particles does 
not necessarily need to be in the peripheral air-
ways. This adds to the robustness of this route of 
administration.
The calculated elimination half-life for inhaled 
levodopa varied between 34 min and 93 min. The 
mean elimination half-life we found in this study 
was 58 min after inhalation of levodopa and 68 min 
after oral administration of levodopa plus decar-
boxylase inhibitor. This is shorter than the half-
life of 90 min previously described in literature.15 
Several previous studies have already confirmed 
that the pharmacokinetics of levodopa display 
considerable interparticipant variation,14 which in 
our study, is the case for AUC, Cmax and elimina-
tion half-life time. Therefore, for a more accurate 
assessment of these parameters, a study popula-
tion larger than eight patients would be desirable.
In none of the patients, a drop in FEV1, FVC or 
MEF50 was observed. Furthermore, none of the 
patients experienced cough or dyspnoea during or 
after the inhalation manoeuvre. In the study 
reported by Lipp and colleagues,18 21.7% of the 
patients reported cough after inhalation of their 
levodopa formulation. A common cause for 
cough after inhalation is the deposition of drug 
particles in the oropharynx. We assume that due 
to the high airflow resistance of the Cyclops 
inhaler,21 deposition of levodopa in the orophar-
ynx is prevented, which explains the absence of 
Table 3. Summary of inhalation parameters obtained from the flow volume curves.
Participant Inhaled volume (l) Maximum Δ pressure 
(kPa)
Peak flow rate (l/min) 
V1 V2 I1 V2I2 V1 V2I1 V2I2 V1 V2I1 V2I2
1 1.9 2.1 2.1 6.0 6.7 6.7 45.4 47.8 47.9
2 2.7 3.0 3.0 6.8 6.5 6.0 48.4 47.2 45.3
3 2.5 2.1 1.9 4.2 3.9 4.3 37.8 36.6 38.5
4 2.8 2.1 2.7 6.4 6.9 10.0 47.0 48.6 58.7
5 2.5 2.6 2.7 2.6 4.3 4.3 30.0 38.5 38.3
6 4.2 4.2 4.1 10.3 10.4 9.6 59.4 59.9 57.4
7 1.8 1.0 1.8 1.5 2.4 3.7 22.9 28.4 33.7
8 2.8 2.5 2.9 3.7 5.0 6.5 35.8 41.4 47.4
V1 = visit 1; V2I1 = visit 2, inhalation 1; V2I2 = visit 2, inhalation 2.
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cough after the levodopa inhalation formulation 
used in this study. Another reason for cough after 
inhalation is the chemical composition of the 
powder.26 Our inhalation powder consists of only 
2% excipient. Since coughing is possibly a reason 
for patients to withdraw inhalation therapy, the 
absence of cough is an important advantage of the 
formulation used in this study.
Whether or not the levodopa plasma concentra-
tions attained by inhalation in this study are suffi-
cient for rescue therapy in off periods will depend 
on disease progression and the degree to which a 
patient is turned ‘off’. In progressed, fluctuating 
patients, a very steep dose–response relationship 
exists, where a maximum effect on finger tapping 
can be achieved by an increase in levodopa effect 
compartment concentration of approximately 
200–400 ng/ml.27 Therefore, the plasma concen-
trations attained by inhalation of levodopa in this 
study (i.e. 229 ng/ml with 30 mg and 476 ng/ml 
with 60 mg) could be clinically sufficient to end off 
episodes in Parkinson’s disease. Because the study 
participants were not in the off state before levo-
dopa inhalation, no effect could be observed. In a 
follow-up clinical trial, we will study the effect of 
inhaled levodopa from the Cyclops DPI on 
Parkinson’s disease patients in the ‘off state’ in 
comparison with orally administered levodopa. 
This will show whether or not the faster absorption 
after inhalation is of clinical benefit.
Conclusion
Oral administration results in a more variable lev-
odopa plasma profile than pulmonary administra-
tion. In addition, inhaled levodopa is absorbed up 
to 85 min faster in the blood plasma and inhaled 
doses of 30 mg and 60 mg showed comparable 
pharmacokinetics per milligram of inhaled levo-
dopa. Since none of the patients experienced 
cough or dyspnoea and no change in pulmonary 
function was measured, it is concluded that the 
new levodopa powder inhalation system is well 
tolerated after inhalation. The results of this study 
therefore suggest that the tested levodopa formu-
lation may be particularly beneficial for use dur-
ing an off period, since a rapid onset of action 
without any harmful effects are two key require-
ments for such a rescue medication. Furthermore, 
no relationship was found between inhalation 
parameters, such as inhaled volume and inhala-
tion flow rate, and levodopa pharmacokinetic 
parameters, which is indicative of a robust admin-
istration method. A study evaluating the efficacy 
of inhaled levodopa from the Cyclops for 
Parkinson’s patients in an off period will be per-
formed next.
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